Active	Status	Sponsor type	Region	Phase	Filter
5 Active 3 Inactive 8 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

5 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
LY007 / China Biotech Services
r/r B-NHL, NCT06279611: An Evaluation of LY007 Cell Injection for	Recruiting	1	18	RoW	LY007	Shanghai Longyao Biotechnology Inc., Ltd., The First Affiliated Hospital with Nanjing Medical University, Ruijin Hospital	B-NHL	08/24	05/26
r/r B-NHL, NCT06364852: An Evaluation of LY007 Cell Injection for	Recruiting	1	18	RoW	LY007	Ruijin Hospital, The First Affiliated Hospital with Nanjing Medical University, Shanghai Longyao Biotechnology Inc., Ltd.	B-NHL	08/24	05/26
NCT04169932: The Clinical Study of CD20 CAR-T Cells in Patients With Relapsed and Refractory B Cell Non-Hodgkin Lymphoma	Recruiting	1	20	RoW	CD20 CAR-T	Shanghai Longyao Biotechnology Inc., Ltd.	Relapsed and Refractory B Cell Lymphoma, Non-Hodgkin Lymphoma	11/22	11/22
LY011 / China Biotech Services
NCT04977193: A Study to Evaluate the Safety and Efficacy of ly011 Cell Injection in the Treatment of Advanced Gastric Adenocarcinoma	Recruiting	1	18	RoW	LY011	Shanghai Longyao Biotechnology Inc., Ltd., The Affiliated Hospital of Xuzhou Medical University	Advanced Gastric Adenocarcinoma	05/23	11/24
NCT04966143: Clinical Study of LY011 in the Treatment of Advanced Pancreatic Cancer	Recruiting	1	30	RoW	LY011	Shanghai Longyao Biotechnology Inc., Ltd.	Pancreatic Cancer	08/23	08/24